Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071381504> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2071381504 endingPage "163" @default.
- W2071381504 startingPage "157" @default.
- W2071381504 abstract "Oncogenic lesions in the cancer cell genome not only alter the intrinsic properties of cancer cells themselves, but also trigger signaling events, the effects of which impact the relationship between tumors and their surrounding host tissues, including the vascular system. Manifestations of the latter include the onset and progression of tumor angiogenesis, and systemic activation of the hemostatic system, a process also known as cancer coagulopathy, or Trousseau syndrome. Indeed, tumor growth, invasion and metastasis are profoundly affected by the properties of the tumor - vascular interface. We postulated earlier that the link between the expression of cancercausing signaling alterations and cancer coagulopathy is at least twofold. First, cancer coagulopathy may emerge indirectly, as an unspecific consequence of vascular permeability and other features of tumor-associated vascular growth, including the pro- and anticoagulant actions of certain angiogenic mediators, some of which (e.g. VEGF) are direct regulatory targets of oncogenes and tumor suppressors. Second, activated oncogenes (K-ras, EGFR or PML-RARα, MET), and/or inactivation of tumor suppressors (e.g. p53 or PTEN) may deregulate some of the hemostatic proteins more directly, i.e. through changes in expression of tissue factor (TF), plasminogen activation inhibitor 1 (PAI-1) and cyclooxygenase 2 (COX-2) [1-4]. In addition to TF expression and release as plasma microvesieles, mutant K-ras may also upregulate expression of thrombin receptors (PAR-1) by cancer cells, thereby possibly rendering such cells hypersensitive to signals emanating from the hemostatic system (e.g. pericellular thrombin). Here, we present an argument that anti-cancer signal transduction inhibitors, also known as ‘targeted agents’ (e.g. Gleevec, Iressa, Erbitux, ATRA) could modulate various vascular processes in cancer, including angiogenesis and cancer coagulopathy, i.e. act as cancer - specific indirect antiangiogenic agents, possibly with a distinct element of anticoagulant activity. Keywords: Tissue factor, cancer, oncogenes, tumor suppressors, angiogenesis" @default.
- W2071381504 created "2016-06-24" @default.
- W2071381504 creator A5015613031 @default.
- W2071381504 creator A5033748917 @default.
- W2071381504 creator A5049270203 @default.
- W2071381504 creator A5081385267 @default.
- W2071381504 date "2007-05-01" @default.
- W2071381504 modified "2023-09-26" @default.
- W2071381504 title "Oncogene-Directed Therapies as Modulators of Cancer Coagulopathy, Angiogenesis and Tumor-Vascular Interface" @default.
- W2071381504 doi "https://doi.org/10.2174/157436207780619473" @default.
- W2071381504 hasPublicationYear "2007" @default.
- W2071381504 type Work @default.
- W2071381504 sameAs 2071381504 @default.
- W2071381504 citedByCount "1" @default.
- W2071381504 crossrefType "journal-article" @default.
- W2071381504 hasAuthorship W2071381504A5015613031 @default.
- W2071381504 hasAuthorship W2071381504A5033748917 @default.
- W2071381504 hasAuthorship W2071381504A5049270203 @default.
- W2071381504 hasAuthorship W2071381504A5081385267 @default.
- W2071381504 hasConcept C121608353 @default.
- W2071381504 hasConcept C126322002 @default.
- W2071381504 hasConcept C186738567 @default.
- W2071381504 hasConcept C203014093 @default.
- W2071381504 hasConcept C2778382381 @default.
- W2071381504 hasConcept C2779013556 @default.
- W2071381504 hasConcept C2779256057 @default.
- W2071381504 hasConcept C2780394083 @default.
- W2071381504 hasConcept C2781018059 @default.
- W2071381504 hasConcept C29537977 @default.
- W2071381504 hasConcept C502942594 @default.
- W2071381504 hasConcept C71924100 @default.
- W2071381504 hasConcept C86803240 @default.
- W2071381504 hasConcept C96232424 @default.
- W2071381504 hasConceptScore W2071381504C121608353 @default.
- W2071381504 hasConceptScore W2071381504C126322002 @default.
- W2071381504 hasConceptScore W2071381504C186738567 @default.
- W2071381504 hasConceptScore W2071381504C203014093 @default.
- W2071381504 hasConceptScore W2071381504C2778382381 @default.
- W2071381504 hasConceptScore W2071381504C2779013556 @default.
- W2071381504 hasConceptScore W2071381504C2779256057 @default.
- W2071381504 hasConceptScore W2071381504C2780394083 @default.
- W2071381504 hasConceptScore W2071381504C2781018059 @default.
- W2071381504 hasConceptScore W2071381504C29537977 @default.
- W2071381504 hasConceptScore W2071381504C502942594 @default.
- W2071381504 hasConceptScore W2071381504C71924100 @default.
- W2071381504 hasConceptScore W2071381504C86803240 @default.
- W2071381504 hasConceptScore W2071381504C96232424 @default.
- W2071381504 hasIssue "2" @default.
- W2071381504 hasLocation W20713815041 @default.
- W2071381504 hasOpenAccess W2071381504 @default.
- W2071381504 hasPrimaryLocation W20713815041 @default.
- W2071381504 hasRelatedWork W1975859778 @default.
- W2071381504 hasRelatedWork W2049739326 @default.
- W2071381504 hasRelatedWork W2058903925 @default.
- W2071381504 hasRelatedWork W2522447413 @default.
- W2071381504 hasRelatedWork W2762132287 @default.
- W2071381504 hasRelatedWork W2931209262 @default.
- W2071381504 hasRelatedWork W2998402275 @default.
- W2071381504 hasRelatedWork W3173207637 @default.
- W2071381504 hasRelatedWork W3175984978 @default.
- W2071381504 hasRelatedWork W4283771460 @default.
- W2071381504 hasVolume "2" @default.
- W2071381504 isParatext "false" @default.
- W2071381504 isRetracted "false" @default.
- W2071381504 magId "2071381504" @default.
- W2071381504 workType "article" @default.